Latest & greatest articles for cannabis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cannabis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cannabis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cannabis

41. Cannabis

Cannabis Top results for cannabis - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for cannabis The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted

2018 Trip Latest and Greatest

42. Cannabis

Cannabis www.ccsa.ca • www.ccdus.ca June 2018 Canadian Drug Summary Canadian Centre on Substance Use and Addiction • Centre canadien sur les dépendances et l’usage de substances Page 1 Cannabis Introduction Cannabis, more commonly called marijuana, is a tobacco-like greenish or brownish material consisting of the dried flowers, fruiting tops and leaves of the cannabis plant, Cannabis sativa. Hashish or cannabis resin is the dried brown or black resinous secretion of the flowering tops (...) of the cannabis plant and can be further processed to produce hash oil, wax or shatter. There is preliminary evidence of higher risks of resins due to the higher concentrations of THC. Cannabis is usually smoked as a cigarette (“joint”) or smoked as resins in a pipe or bong, also known as “dabbing.” 1 Vaporizers are also used to reduce the toxins inhaled from cannabis smoke. Some individuals who use cannabis slice open and hollow out cigars and replace the tobacco with marijuana (called “blunts”). In some

2018 Canadian Centre on Substance Abuse

43. Daily use of high-potency cannabis is associated with an increased risk of admission and more intervention after first-episode psychosis

Daily use of high-potency cannabis is associated with an increased risk of admission and more intervention after first-episode psychosis Daily use of high-potency cannabis is associated with an increased risk of admission and more intervention after first-episode psychosis | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies (...) , please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Daily use of high-potency cannabis is associated with an increased risk of admission and more intervention after

2018 Evidence-Based Mental Health

44. Therapeutic Cannabis and Endocannabinoid Signaling System Modulator Use in Otolaryngology Patients (Full text)

Therapeutic Cannabis and Endocannabinoid Signaling System Modulator Use in Otolaryngology Patients 1) review benefits and risks of cannabis use, with emphasis on otolaryngic disease processes; 2) define and review the endocannabinoid signaling system (ESS); and 3) review state and federal regulations for the use and research of cannabis and ESS modulators.This manuscript is a review of the current literature relevant to the stated objectives.Cannabis (marijuana) use is increasing (...) . It is the most widely used illicit substance in the world. There is increasing interest in its therapeutic potential due to changing perceptions, new research, and legislation changes controlling its use. The legal classification of cannabis is complicated due to varied and conflicting state and federal laws. There are currently two synthetic cannabinoid drugs that are FDA approved. Current indications for use include chemotherapy-related nausea and vomiting, cachexia, and appetite loss. Research has

2018 Laryngoscope investigative otolaryngology PubMed

45. Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence (Full text)

Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence Review evidence for cannabinoids as adjunctive treatments for treatment-resistant epilepsy. Systematic search of Medline, Embase and PsycINFO was conducted in October 2017. Outcomes were: 50%+ seizure reduction, complete seizure freedom; improved quality of life (QoL). Tolerability/safety were assessed by study withdrawals, adverse events (AEs) and serious adverse events (SAEs

2018 EvidenceUpdates PubMed

46. Cannabis-based medicines for chronic neuropathic pain in adults. (PubMed)

Cannabis-based medicines for chronic neuropathic pain in adults. This review is one of a series on drugs used to treat chronic neuropathic pain. Estimates of the population prevalence of chronic pain with neuropathic components range between 6% and 10%. Current pharmacological treatment options for neuropathic pain afford substantial benefit for only a few people, often with adverse effects that outweigh the benefits. There is a need to explore other treatment options, with different mechanisms (...) of action for treatment of conditions with chronic neuropathic pain. Cannabis has been used for millennia to reduce pain. Herbal cannabis is currently strongly promoted by some patients and their advocates to treat any type of chronic pain.To assess the efficacy, tolerability, and safety of cannabis-based medicines (herbal, plant-derived, synthetic) compared to placebo or conventional drugs for conditions with chronic neuropathic pain in adults.In November 2017 we searched CENTRAL, MEDLINE, Embase

2018 Cochrane

47. Medical Cannabis Use in the Elderly: Clinical Effectiveness and Guidelines

Medical Cannabis Use in the Elderly: Clinical Effectiveness and Guidelines Medical Cannabis Use in the Elderly: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Medical Cannabis Use in the Elderly: Clinical Effectiveness and Guidelines Medical Cannabis Use in the Elderly: Clinical Effectiveness and Guidelines Published on: December 21, 2017 Project Number: RA0944-000 Product Line: Research Type: Drug Report Type: Reference List Result type: Report Question What (...) is the clinical effectiveness on the use of medical cannabis in the elderly? What are the evidence-based guidelines on the use of medical cannabis in the elderly? Key Message One systematic review, four randomized controlled trials, and two non-randomized studies were identified regarding the clinical effectiveness on the use of medical cannabis in the elderly. Tags geriatrics, aged, cannabinoids, cannabis, marijuana abuse, older adult, Elderly Files Rapid Response Reference List Published : December 21, 2017

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

48. Efficacy of Cannabis-Based Medicines for Pain Management: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Efficacy of Cannabis-Based Medicines for Pain Management: A Systematic Review and Meta-Analysis of Randomized Controlled Trials The management of chronic pain is a complex challenge worldwide. Cannabis-based medicines (CBMs) have proven to be efficient in reducing chronic pain, although the topic remains highly controversial in this field.This study's aim is to conduct a conclusive review and meta-analysis, which incorporates all randomized controlled trials (RCTs) in order to update clinicians (...) , cannabinoids have marked effects, so that inadequate blinding of the placebo could constitute an important source of limitation in these types of studies.The current systematic review suggests that CBMs might be effective for chronic pain treatment, based on limited evidence, primarily for neuropathic pain (NP) patients. Additionally, GI AEs occurred more frequently when CBMs were administered via oral/oromucosal routes than by inhalation.Key words: Cannabis, CBMs, chronic pain, postoperative pain, review

2017 EvidenceUpdates

49. Examining the Impact of Decriminalizing or Legalizing Cannabis for Recreational Use

Examining the Impact of Decriminalizing or Legalizing Cannabis for Recreational Use McMaster Health Forum 1 Evidence >> Insight >> Action Supported by the Michael G. DeGroote Initiative for Innovation in Healthcare Rapid Synthesis Examining the Impact of Decriminalizing or Legalizing Cannabis for Recreational Use 31 July 2017 McMaster Health Forum 1 Evidence >> Insight >> Action Rapid Synthesis: Examining the Impact of Decriminalizing or Legalizing Cannabis for Recreational Use 30-day response (...) 20 June 2017 20 JUNE 2017 Examining the Impact of Decriminalizing or Legalizing Cannabis for Recreational Use 2 Evidence >> Insight >> Action McMaster Health Forum and Forum+ The goal of the McMaster Health Forum, and its Forum+ initiative, is to generate action on the pressing health- and social-system issues of our time, based on the best available research evidence and systematically elicited citizen values and stakeholder insights. We aim to strengthen health and social systems – locally

2017 McMaster Health Forum

50. Integrated Cessation Programs for Adults Who Smoke Cannabis and Tobacco: Clinical Effectiveness and Guidelines

Integrated Cessation Programs for Adults Who Smoke Cannabis and Tobacco: Clinical Effectiveness and Guidelines Integrated Cessation Programs for Adults Who Smoke Cannabis and Tobacco: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Integrated Cessation Programs for Adults Who Smoke Cannabis and Tobacco: Clinical Effectiveness and Guidelines Integrated Cessation Programs for Adults Who Smoke Cannabis and Tobacco: Clinical Effectiveness and Guidelines Published (...) on: September 28, 2017 Project Number: RA0934-000 Product Line: Research Type: Devices and Systems Report Type: Reference List Result type: Report Question What is the clinical effectiveness of integrated cessation programs in adults who smoke cannabis and tobacco? What are the evidence-based guidelines associated with the use of integrated cessation programs in adults who smoke cannabis and tobacco? Key Message One systematic review with meta-analysis and one randomized controlled trial were identified

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

51. Pharmacological Interventions for the Prevention or Treatment of Cannabis Use: Clinical Effectiveness and Guidelines

Pharmacological Interventions for the Prevention or Treatment of Cannabis Use: Clinical Effectiveness and Guidelines Pharmacological Interventions for the Prevention or Treatment of Cannabis Use: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Pharmacological Interventions for the Prevention or Treatment of Cannabis Use: Clinical Effectiveness and Guidelines Pharmacological Interventions for the Prevention or Treatment of Cannabis Use: Clinical Effectiveness (...) and Guidelines Published on: September 22, 2017 Project Number: RA0933-000 Product Line: Research Type: Drug Report Type: Reference List Result type: Report Question What is the clinical effectiveness of pharmacological interventions for the prevention or treatment of cannabis use in adults? What are the evidence-based guidelines associated with the use of pharmacological interventions for the prevention or treatment of cannabis use in adults? Key Message Four systematic reviews and two randomized controlled

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

52. Psychological and Psychosocial Interventions for the Prevention or Treatment of Cannabis Use: Clinical Effectiveness and Guidelines

Psychological and Psychosocial Interventions for the Prevention or Treatment of Cannabis Use: Clinical Effectiveness and Guidelines Psychological and Psychosocial Interventions for the Prevention or Treatment of Cannabis Use: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Psychological and Psychosocial Interventions for the Prevention or Treatment of Cannabis Use: Clinical Effectiveness and Guidelines Psychological and Psychosocial Interventions (...) for the Prevention or Treatment of Cannabis Use: Clinical Effectiveness and Guidelines Published on: September 15, 2017 Project Number: RA0932-000 Product Line: Research Type: Devices and Systems Report Type: Reference List Result type: Report Question What is the clinical effectiveness of psychological and psychosocial interventions for the prevention or treatment of cannabis use in adults? What are the evidence-based guidelines associated with the use of psychological and psychosocial interventions

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

53. Benefits and Harms of Plant-Based Cannabis for Posttraumatic Stress Disorder: A Systematic Review. (Full text)

Benefits and Harms of Plant-Based Cannabis for Posttraumatic Stress Disorder: A Systematic Review. Cannabis is available from medical dispensaries for treating posttraumatic stress disorder (PTSD) in many states of the union, yet its efficacy in treating PTSD symptoms remains uncertain.To identify ongoing studies and review existing evidence regarding the benefits and harms of plant-based cannabis preparations in treating PTSD in adults.MEDLINE, the Cochrane Library, and other sources from (...) database inception to March 2017.English-language systematic reviews, trials, and observational studies with a control group that reported PTSD symptoms and adverse effects of plant-based cannabis use in adults with PTSD.Study data extracted by 1 investigator was checked by a second reviewer; 2 reviewers independently assessed study quality, and the investigator group graded the overall strength of evidence by using standard criteria.Two systematic reviews, 3 observational studies, and no randomized

2017 Annals of Internal Medicine PubMed

54. The Effects of Cannabis Among Adults With Chronic Pain and an Overview of General Harms: A Systematic Review. (Full text)

The Effects of Cannabis Among Adults With Chronic Pain and an Overview of General Harms: A Systematic Review. Cannabis is increasingly available for the treatment of chronic pain, yet its efficacy remains uncertain.To review the benefits of plant-based cannabis preparations for treating chronic pain in adults and the harms of cannabis use in chronic pain and general adult populations.MEDLINE, Cochrane Database of Systematic Reviews, and several other sources from database inception to March (...) 2017.Intervention trials and observational studies, published in English, involving adults using plant-based cannabis preparations that reported pain, quality of life, or adverse effect outcomes.Two investigators independently abstracted study characteristics and assessed study quality, and the investigator group graded the overall strength of evidence using standard criteria.From 27 chronic pain trials, there is low-strength evidence that cannabis alleviates neuropathic pain but insufficient

2017 Annals of Internal Medicine PubMed

55. Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations

Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations Cannabis use is common in North America, especially among young people, and is associated with a risk of various acute and chronic adverse health outcomes. Cannabis control regimes are evolving, for example toward a national legalization policy in Canada, with the aim to improve public health, and thus require evidence-based interventions. As cannabis-related health outcomes may be influenced by behaviors (...) that are modifiable by the user, evidence-based Lower-Risk Cannabis Use Guidelines (LRCUG)-akin to similar guidelines in other health fields-offer a valuable, targeted prevention tool to improve public health outcomes.To systematically review, update, and quality-grade evidence on behavioral factors determining adverse health outcomes from cannabis that may be modifiable by the user, and translate this evidence into revised LRCUG as a public health intervention tool based on an expert consensus process.We used

2017 EvidenceUpdates

56. Severity and outcomes of acute alcoholic pancreatitis in cannabis users (Full text)

Severity and outcomes of acute alcoholic pancreatitis in cannabis users Cannabis is the most commonly and widely used illicit drug in the world and is also the most commonly used drug of abuse in alcohol drinkers. Experimental studies have shown conflicting results of the effects of cannabis on the severity of acute pancreatitis (AP). The purpose of this study is to ascertain the clinical effects of simultaneous alcohol and cannabis use on severity at presentation and outcomes of acute (...) alcoholic pancreatitis (AAP).A retrospective review was conducted on the patients discharged with principle or secondary diagnosis of AP using ICD-9 & ICD-10 codes during the time period from January 2006 to December 2015 at a large community-based hospital in Central Georgia. Patients with alcoholic pancreatitis with cannabis (CB+) and without cannabis (CB-) use were identified and were matched with sex and age.Our study findings showed that a greater percentage of CB+ patients did not have a systemic

2017 Translational gastroenterology and hepatology PubMed

57. Medical Cannabis or Cannabinoids for the Treatment of Insomnia Disorder in Adults: Clinical Effectiveness and Guidelines

Medical Cannabis or Cannabinoids for the Treatment of Insomnia Disorder in Adults: Clinical Effectiveness and Guidelines Medical Cannabis or Cannabinoids for the Treatment of Insomnia Disorder in Adults: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Medical Cannabis or Cannabinoids for the Treatment of Insomnia Disorder in Adults: Clinical Effectiveness and Guidelines Medical Cannabis or Cannabinoids for the Treatment of Insomnia Disorder in Adults: Clinical (...) Effectiveness and Guidelines Published on: June 26, 2017 Project Number: RB1113-000 Product Line: Research Type: Drug Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of medical cannabis or cannabinoids for the treatment of insomnia disorder in adults? What are the evidence-based guidelines regarding the use of medical cannabis or cannabinoids for the treatment of insomnia disorder in adults? Key Message One randomized controlled trial and one non-randomized

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

58. Cannabis and Canada?s children and youth

Cannabis and Canada?s children and youth Cannabis is the most common illicit drug used worldwide and it is used frequently by Canadian teenagers. Cannabis use during adolescence can cause functional and structural changes to the developing brain, leading to damage. Marijuana use in this age group is strongly linked to: cannabis dependence and other substance use disorders; the initiation and maintenance of tobacco smoking; an increased presence of mental illness, including depression, anxiety (...) and psychosis; impaired neurological development and cognitive decline; and diminished school performance and lifetime achievement. Rates of acute medical care and hospitalization for younger children who have ingested cannabis unintentionally are increasing. Ongoing debate concerning cannabis regulation in Canada makes paying close attention to the evidence for its health effects and ensuring that appropriate safeguards are in place, vital public health priorities. Keywords: Adolescents, CUD, CWS

2017 Canadian Paediatric Society

59. Cost of Cannabis Collisions in Canadian Provinces in 2012 [infographic]

Cost of Cannabis Collisions in Canadian Provinces in 2012 [infographic] COST PER INCIDENT © Canadian Centre on Substance Use and Addiction 2017. ® State Farm and related trademarks and logos are registered trademarks owned by State Farm Mutual Automobile Insurance Company, used under licence by Certas Home and Auto Insurance Company and certain of its affiliates. To learn more read the report at a glance PROPERTY DAMAGE ONLY $10,700 68 % $84,600 59 % $8,532,200 61 % INJURIES VICTIMS (...) BY COLLISION TYPE FATALITIES Cost of Cannabis Collisions in Canadian Provinces in 2012 $1.09 BILLION in economic and social costs 7,794 75 4,407 THOSE 34 YEARS OF AGE AND YOUNGER ACCOUNT FOR APPROXIMATELY + + + OF THESE COSTS $658 Million 16–34 YEAR OLDS ACCOUNT FOR THE MAJORITY OF VICTIMS Reference: Wettlaufer, A., Florica, R.O., Asbridge, M., Beirness, D., Brubacher, J., Callaghan, J.R., … Rehm, J. (2017). Estimating the harms and costs of cannabis-attributable collisions in the Canadian provinces. Drug

2017 Canadian Centre on Substance Abuse

60. Collisions Attributable to Cannabis: Estimating the Harms and Costs in the Canadian Provinces (Report at a Glance)

Collisions Attributable to Cannabis: Estimating the Harms and Costs in the Canadian Provinces (Report at a Glance) www.ccsa.ca • www.cclt.ca Report at a Glance Canadian Centre on Substance Use and Addiction • Centre canadien sur les dépendances et l’usage de substances Page 1 Collisions Attributable to Cannabis: Estimating the Harms and Costs in the Canadian Provinces After alcohol, cannabis is the most widely used psychoactive substance in Canada and cannabinoids are among the most common (...) psychoactive substances found in dead and injured drivers in Canada (Beasley & Beirness, 2011; Brubacher et al., 2016). In 2012, approximately 10% of Canadians aged 15 and older used cannabis and just under half of those reported driving within two hours of using it (Health Canada, 2012). However, there remains a lot that we don’t know about the extent and costs associated with driving under the influence of cannabis (DUIC). As Canada is poised to introduce legislation to regulate cannabis, conversations

2017 Canadian Centre on Substance Abuse